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Resistance to 5-Fluorouracil (5-FU) is a major obstacle to the successful treatment of
colorectal cancer (CRC) and posed an increased risk of recurrence. DNA methylation
has been suggested as one of the underlying mechanisms for recurrent disease
and its contribution to the development of drug resistance remains to be clarified.
This study aimed to determine the methylation phenotype in CRC for identification
of predictive markers for chemotherapy response. We performed DNA methylation
profiling on 43 non-recurrent and five recurrent CRC patients using the Illumina Infinium
HumanMethylation450 Beadchip assay. In addition, CRC cells with different genetic
backgrounds, response to 5-FU and global methylation levels (HT29 and SW48) were
treated with 5-FU and DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-azadC).
The singular and combined effects of these two drug classes on cell viability and
global methylation profiles were investigated. Our genome-wide methylation study
on the clinical specimens showed that recurrent CRCs exhibited higher methylation
levels compared to non-recurrent CRCs. We identified 4787 significantly differentially
methylated genes (P < 0.05); 3112 genes were hyper- while 1675 genes were
hypomethylated in the recurrent group compared to the non-recurrent. Fifty eight and
47 of the significantly hypermethylated and hypomethylated genes have an absolute
recurrent/non-recurrent methylation difference of ≥20%. Most of the hypermethylated
genes were involved in the MAPK signaling pathway which is a key regulator for
apoptosis while the hypomethylated genes were involved in the PI3K-AKT signaling
pathway and proliferation process. We also demonstrate that 5-azadC treatment
enhanced response to 5-FU which resulted in significant growth inhibition compared to
5-FU alone in hypermethylated cell lines SW48. In conclusion, we found the evidence of
five potentially biologically important genes in recurrent CRCs that could possibly serve
as a new potential therapeutic targets for patients with chemoresistance. We postulate
that aberrant methylation of CCNEI, CCNDBP1, PON3, DDX43, and CHL1 in CRC might
be associated with the recurrence of CRC and 5-azadC-mediated restoration of 5-FU
sensitivity is mediated at least in part by MAPK signaling pathway.
Keywords: epigenetics, DNA methylation, colorectal cancer, 5-fluorouracil, 5-aza-2′-deoxycytidine,
chemoresistance, recurrent cancer
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in
worldwide contributing to 10% of the total new cancer cases
and 9% of cancer deaths in 2012 (Ferlay et al., 2015). The high
incidence and mortality demonstrate the global CRC burden. The
disease burden is similar in Malaysia where CRC is the second
most common cancer diagnosed among males and third common
cancer in females. According to the National Cancer Registry
(NCR) Report in the year 2011, 2246 CRC cases were reported in
2007, contributing to 12.3% of total cancer cases (Zainal Ariffin
and Nor Saleha, 2011). Of these, 1185 cases were males and 1101
cases females.
To date, various treatment strategies have been used to treat
CRC depending on the stage at which cancer was discovered.
In the early stages of CRC (Stages I and II), surgery is the
best option (Holen and Chung, 2008). However, for advanced
stages such as stage III and stage IV, treatment often consist
of a combination of therapies such as surgery, chemotherapy
and/or radiotherapy to minimize the risk of recurrence (Hayat,
2009). Managing CRC remains a clinical obstacle, as more
than 15% of cases are resistant to 5-Fluorouracil (5-FU)-based
chemotherapeutic regimens which is the mainstay of treatment,
and tumor recurrence rates can be as high as 50–60% (Shakibaei
et al., 2014). Furthermore, most of recurrence cases occur in the
first 3 years after a surgery and the majority started to recur in
the second year (Aghili et al., 2010). Various factors have been
proposed to play a significant role in CRC recurrence and one of
the factors is chemotherapy resistance (Kanwar et al., 2012).
Epigenetic alterations have been suggested as one of the
underlying mechanisms of chemotherapy resistance (Zeller and
Brown, 2010). One major epigenetic mechanism involved in
the progression of cancer is DNA methylation which refer to
the enzymatic addition of a methyl group to the 5′ position of
cytosine ring by DNA methyltransferase (DNMT) to produce
5-methylcytosine (Bestor, 2000). Altered DNA methylation
patterns can influence the expression of the genes by silencing
or activating the genes. In general, there are two types of aberrant
DNA methylation that could contribute to the development and
progression of cancer which are global DNA hypomethylation
and CpG island hypermethylation (Wajed et al., 2001).
The term DNA hypomethylation refers to global decrease
in the level of methylation in the genome of tumor cells in
comparison to normal tissue (Lao and Grady, 2011). On the
contrary, hypermethylation is an increase of DNA methylation
level at CpG island as compared to normal tissue. Methylation of
CpG islands within the promoter of CRC results in silencing of
tumor suppressor genes and promote tumor formation (Herman
and Baylin, 2003). Methylation of CpG islands at particular genes
may also contribute to the acquisition of drug resistance. This
was demonstrated by Arnold et al. (2003) whereby methylation
of CpG island in the MLH1 gene is associated with resistance
to 5-FU and development of chemoresistance could increase the
incidence of recurrence CRC. However, this process is reversible
and could be achieved by using demethylating agent such
as 5-aza-2′-deoxycytidine (5-azadC). Therefore, identification
of DNA methylation patterns in cancer may be helpful in
predicting prognosis and response to chemotherapeutic agents.
In addition, to the best of our knowledge there have been
very limited studies which investigate global DNA methylation
profile in recurrent CRC. Moreover, at the time this research
was conducted there is no study which investigate the global
methylation changes in in vitro CRC model upon treatment
with combination of 5-FU with 5-azadC. Thus, the aim of
the study was to investigate the methylation phenotype in
CRC on the global scale using the high density Infinium
DNA Methylation 450K DNA assay in order to identify
predictive markers for chemotherapy response. The second aim
was to investigate the magnitude of 5-azadC in enhancing
5-FU chemosensitivity and to determine the global methylation
changes in cells treated with 5-FU, 5-azadC or combination of
both agents.
MATERIALS AND METHODS
Clinical Samples, Cell Lines, and Culture
Condition
This study was carried out in accordance with the
recommendations of Universiti Kebangsaan Malaysia Research
Ethics Committee (Reference number: UKM 1.5.3.5/244/UMBI-
001-2014) with written informed consent from all subjects.
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The protocol was approved by the
Universiti Kebangsaan Malaysia Research Ethics Committee.
Forty eight consented CRC patients from Hospital Universiti
Kebangsaan Malaysia (HUKM), Malaysia were included in this
study; 43 samples were non-recurrent and five were recurrent
cases. All patients were Malaysian citizen diagnostically
confirmed with primary or recurrent CRC without other cancer
history. The tumor samples were from patients who underwent
surgery for CRC and have not yet started chemotherapy while
those associated with recurrent disease were obtained after the
chemotherapy. Formalin fixed, paraffin embedded (FFPE) tissues
were collected if frozen tissues were not available.
HT29 and SW48 cell lines were obtained from American
Type Culture Collection (ATCC) and maintained in McCoy’s 5A
(Gibco) and DMEM (Gibco), respectively at 37◦C and 5% CO2
in incubator (Galaxy 170R, Eppendorf). Both culture media were
supplemented with 10% fetal bovine serum (FBS) (Gibco).
Tissue Processing and DNA Extraction
The surgically resected tissues were immediately frozen in liquid
nitrogen and stored at −80◦C before further analysis. All tissues
were sectioned and stained with Hematoxylin and Eosin (H&E).
Only tissues that contain more than 80% of tumor cells were
used. DNA from fresh frozen tissues and cell lines were extracted
using QIAamp DNA mini kit while QIAamp DNA FFPE tissue
kit (both from Qiagen) was used for FFPE specimens according to
the manufacturer’s instructions. The quantification and purity of
total DNA for each sample were determined by using Nanodrop
ND-2000 spectrophotometer (NanoDrop Technologies, Inc.).
Only samples with purity from 1.8 to 2.05 were selected for the
microarray study.
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Drugs Treatment and Cell Viability Assay
The cells were seeded in 96-well plates at 1 × 104 cells/well
and incubated with chemotherapeutic drug 5FU, demethylating
agent 5-azadC (both from Sigma) or combination of both for
72 h at different concentration (ranges from 10 to 100 µM)
(Flis et al., 2014) and the culture media was replaced
every 24 h with fresh media. All agents were dissolved in
dimethyl sulfoxide (DMSO) (Nacalai Tesque) and then
diluted in the culture media for experiment. The untreated
cells served as a control and were treated simultaneously
with DMSO (Nacalai Tesque) with final concentration
of 0.2%.
DNA Methylation Profiling and Data
Analysis
In all cases, 500 ng of DNA was chemically modified to
convert all unmethylated cytosine to uracil by the EZ DNA
methylation – Gold kit (Zymo Research, Inc.) according to
the manufacturer’s protocol. The Infinium DNA Methylation
450K assay was performed according to the manufacturer’s
specifications (Illumina, Inc.). The Illumina Infinium DNA
methylation 450K assay examines the DNA methylation status of
485577 CpG dinucleotides distributed over the whole genome.
The raw idat files obtained from methylation microarray
were analyzed using the CHAMP Bioconductor packages
(Morris et al., 2014; Butcher and Beck, 2015). Filters were
applied to all datasets where CpG sites that had detection
P-values of greater than 0.01 in one or more samples were
excluded from further analysis. The raw intensities were SWAN-
normalized to reduce the technical biases inherent in the
probe design before statistical analysis (Maksimovic et al.,
2012). Once normalization has been performed, β-values were
extracted. Statistical analysis was performed on the β-value.
Differentially methylated CpG sites were determined using t
statistics from the limma Bioconductor package (Morris and
Beck, 2015). We further used the filtering characteristic of P-value
at P < 0.05 to identify significant differentially methylated
genes.
Validation of Methylation Microarray
Using MS–qPCR
A total of five significant genes differentially methylated in
recurrent versus non-recurrent samples CCNE1 (EPSH107315-
1A), DDX43 (EPSH112573-1A), CHL1 (EPSH110000-1A),
PON3 (EPSH113282-1A), and CCNDBP1 (EPSH104489-
1A) were selected from the DNA methylation profile for
validation using EpiTect Methyl II PCR assays (SABiosciences)
following the manufacturer’s protocol. Methylation-sensitive
(EPHS115450-1A) and methylation-dependent (EPHS115451-
1A) digest control assays were performed on 34 fresh tissue
samples (31 non-recurrent and 3 recurrent tumors). Digested
DNA was used as template for qPCR assay using RT2 SYBR
Green ROX qPCR Mastermixes (SABiosciences, #330520) under
standard amplification conditions on Applied Biosystem
7500 Fast Real-Time PCR system (Applied Biosystems,
Inc.). Data generated by MS-qPCR were further analyzed
as recommended by the manufacturer1. Meanwhile, two
FFPE samples of recurrent tumor were validated using
methylated and unmethylated primers designed from AIT
Biotech, Singapore. The bisulfite conversion was performed
using EpiTect Bisulfite Kit (SABiosciences) according to
the manufacturer’s instruction. MS-qPCR was carried out
using Methylamp TM MS-qPCR Kit (Epigentek Group,
Inc.) according to the manufacturer’s protocol on Applied
Biosystem 7500 Fast Real-Time PCR system (Applied Biosystems,
Inc.).
Statistical Analysis
For cell viability analysis, all statistical analyses were performed
using GraphPad Prism 6.0 statistical software. Experimental
data was presented as mean ± standard deviation (S.D). Cell
viability was analyzed by two-way ANOVA test. P < 0.05 was
assumed statistically significant and marked with asterisks on
graphs. All experiments were conducted in triplicates to ensure
reproducibility of the results.
RESULTS
Distribution of Hyper- and
hypomethylated Probes in Recurrent
versus Primary CRCs
Clinicopathological characteristic of the 48 tumor samples are
tabulated in Table 1. Majority of the patients were male and age
more than 50 years. For the analysis of microarray methylation
data, probe filtering was performed to remove probes that failed
to hybridize with a detection P > 0.01 in more than one sample
and probes that are not represented by a minimum of three beads
on the array. This resulted in 426,411 probes for the downstream
1http://www.sabiosciences.com/dna_methylation_data_analysis.php/
TABLE 1 | Clinicopathological characteristics of 48 CRC samples
comprised of 43 non-recurrent and 5 recurrent CRCs.
Characteristics Non-recurrent samples (%) Recurrent samples (%)
Gender
Female 17 (39.5%) 1 (20%)
Male 26 (60.5%) 4 (80%)
Age (years)
≤50 1 (2.30%) 3 (60%)
>50 42 (97.7%) 2 (40%)
Ethnicity
Malay 19 (44.1%) 3 (60%)
Chinese 22 (51.1%) 2 (40%)
India 1 (2.40%)
Others 1 (2.40%)
Duke’s staging
A 3 (7.0%) –
B 16 (37.2%) –
C 24 (55.8%) –
Recurrent 5 (100%)
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analysis. We then generated the principal component analysis
(PCA) to see the clustering among the samples. The PCA plot
showed that recurrent CRCs were clustered distinctly compared
to the non-recurrent samples (Supplementary Figure S1).
In order to analyze DNA methylation differences between
recurrent and non-recurrent tumors, we examined the average
β-values between both groups. A total of 6820 probes were
significantly differentially methylated between recurrent and
non-recurrent tumor. Each differentially methylated genes were
visualized in the volcano plot (Figure 1). Of these 6820
differentially methylated CpGs, 4409 were hypermethylated
and 2411 were hypomethylated (Figure 2A). From the 4409
differentially hypermethylated probes, 1593 probes were located
in the island region, 1522 probes were located in the shore
region, 202 probes were in the shelve region and the remaining
1092 probes were in the open sea (Figure 2B). In contrast
to hypermethylation, most of the hypomethylated CpGs were
located in the open sea area of genome followed by island, shores
and shelves with 925, 777, 510, and 199 probes, respectively
(Figure 2C).
Out of 6820 differentially methylated probes, those
hypermethylated in recurrent tumor compared to non-
recurrent tumor were associated with 3112 genes while 1675
genes were hypomethylated in recurrent samples. Heatmap of
the significantly differentially methylated genes in recurrent
versus primary CRC is shown in Figure 3. Our genome-wide
methylation study in CRC showed that recurrent CRCs exhibited
increased methylation level compared to non-recurrent CRCs.
Fifty eight and 47 of the significantly hypermethylated and
hypomethylated genes have an absolute recurrent/non-recurrent
methylation difference of≥20% (Supplementary Table S1-1). The
FIGURE 1 | Volcano plot representing differentially methylated probes.
The significantly hypermethylated probes are shown in red while
hypomethylated probes are shown in blue (P < 0.05).
top 10 significantly differentially methylated genes are TECTA,
EIF2C2, FAM167B, SMAD3, ZFYVE20, PAM, RAI1, SATB1,
FAM175A, and NFATC2 (average 1β-value between recurrent
and non-recurrent group of −0.144, 0.137, 0.208, 0.269, −0.132,
0.167, 0.205, 0.093, 0.104, and 0.124, respectively) (Figure 4).
Pathways Enrichment analyses of
Differentially Methylated Genes
Next, the list of hypermethylated and hypomethylated genes
were subjected to pathway enrichment analysis using the DAVID
(Huang et al., 2003, 2009). We found five significant enriched
pathways of hypermethylated genes that are potentially involved
in the recurrent CRCs, namely, pathways in cancer, MAPK
signaling pathway, focal adhesion, calcium signaling pathway
and Wnt signaling pathway (Table 2A). The MAPK signaling
pathway which is known to be associated with CRC, showed
hypermethylation of 56 genes that were mostly regulating the
apoptosis process.
Conversely, the hypomethylated genes in recurrent CRCs were
associated with pathways in cancer, neuroactive ligand-receptor
interaction, endocytosis, regulation of actin cytoskeleton and
focal adhesion (Table 2B). For the pathways in cancer, the genes
specifically involved are in the PI3K-AKT signaling pathway
and proliferation process. The genes involved in this signaling
pathway and proliferation process include PI3K, PPFP, RXR,
EGFR, CCNA1, and E2F. We also performed gene ontology (GO)
enrichment analysis to classify the hyper- and hypomethylated
genes into the categories of cellular component, biological
process and molecular function. In the cellular component
category, 25–30% of the hyper- and hypomethylated genes are
shown to be intrinsic to membrane (Figure 5). For the molecular
function and biological process, the hypermethylated genes were
enriched for transcription regulator activity and intracellular
signaling cascade (Figure 5A), while the hypomethylated genes
were enriched for ion binding and regulation of transcription
(Figure 5B).
Validation of the HumanMethylation450
Beadchip Array
A total of three differentially hypermethylated genes (CCNE1,
PON3, and CCNDBP1) and two differentially hypomethylated
genes (DDX43 and CHL1) were selected for the validation based
on their β-value and association with CRC as well as other
cancers. We explored the function of these genes using the
Pathway Studio software. These genes were mostly involved in
cell cycle, cell proliferation and cell growth as shown in Figure 6.
The methylation pattern of validation using EpiTect Methyl
II PCR assay were in concordance with methylation profiling
(Supplementary Figure S2).
Growth Studies and Effects of
Combination Treatments of 5-FU with
5-azadC
Cell viability assay was performed on HT29 and SW48 after
treatment with 5-FU, 5-AzadC or combination of both drugs.
Firstly, the effect of 5-FU alone on HT29 and SW48 cell viability
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FIGURE 2 | Description of the 450K DNA methylation array. (A) General overview of significantly differentially methylated probes in relation to CpG content and
neighborhood context. (B) Hypermethylated probes and (C) Hypomethylated probes according to CpG content and neighborhood context.
was examined. Both cells were treated with concentration ranges
from 10 to 50 µM. The results of cell viability assays indicated
that HT29 showed more inhibition of cells as the concentration of
5-FU increased compared to SW48 (Figure 7A). The decrease of
HT29 cell viability is more than 50% even at lowest concentration
(10 µM). For SW48, the cell viability decreased only 25% at
the 10 µM and only reached 50% inhibition at higher dose
(20 µM 5-FU). We also observed the effect of 5-AzadC on
both cells at concentration ranges from 20 to 100 µM for
72 h (Figure 7B). Inhibition of cell viability by 5-AzadC was
more prominent in SW48 compared to HT29 (30–50% versus
25–30%). Nonetheless, all the cells treated with either drugs
showed significant reduction in cell viability compared to the
untreated cells (P < 0.05).
Apart from that, we also examined the effect of 5-FU in
combination with 5-AzadC on CRC cell survival at various
concentrations. The effect of combining both drugs at lowest
concentration is more promising in SW48 cells (60% inhibition)
compared to the treatment with 5-FU (25% inhibition) or 5-
AzadC alone (30% inhibition) (Figure 7C). This showed that
5-azadC enhanced the inhibitory effects of 5-FU in SW48 even
at the lowest concentration tested (10 µM). On the contrary,
combinatorial drugs treatment on HT29 cells showed lower
reduction in cell viability (50% inhibition) compared to 5-FU
alone (70% inhibition).
Global Methylation Response to 5-FU
and 5-azadC
Following the treatment of cells with all drugs over 72 h,
methylation profiling was performed on both cells in order
to identify methylation pattern cause by the chemotherapeutic
and/or demethylating agent. Methylation profiling of combined
5-FU and 5-AzadC treatment was performed on SW48 and HT29
to observe whether combination treatment would reverse the
process of methylation or remains unchanged. Moreover, we also
performed methylation profiling on cells that treated with 5-FU
or 5-AzadC only in order to compare the methylation level of
combined treatment. The cells treated with 20 µM of 5-FU and
40 µM of 5-AzadC were chosen based on the concentration at
which cell viability was reduced by 50%.
Treatment with 5-FU in HT29 caused 70% reduction in cell
viability with significant hypermethylation of only five genes and
hypomethylation of four genes (Supplementary Tables S1-1 and
S1-2). On the other hand, 5-azadC not only caused significant
hypomethylation of 329 genes but also induced hypermethylation
of 172 genes (Supplementary Table S1-3). Despite higher number
of aberrantly methylated genes, the impact on cell viability is
lesser compared to 5-FU (30%). Combination of both 5-FU and
5-azadC resulted in 114 hypermethylated and 68 hypomethylated
genes (Supplementary Tables S1-1–S1-4) with 55% reduction in
cell viability. Since 5-FU alone was able to reduce cancer cell
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FIGURE 3 | Heatmap of 50 differentially methylated genes in recurrent versus non-recurrent cases. Samples were clustered based on 4787 significant
differentially methylated genes at P < 0.05. The row represents individual genes and the column represents individual samples. The pink color indicates recurrent
cases and purple color indicates non-recurrent cases. The color in each small boxes represents the methylation level of the genes. The red boxes indicate genes that
are hypermethylated while blue boxes represent genes that are hypomethylated.
viability in HT29 even at the lowest concentration tested (10µM),
chemosensitization using 5-azadC is deemed unnecessary.
At 20 µM, 5-FU treatment in SW48 caused 60% reduction
in cell viability with hypermethylation of 313 genes and
hypomethylation of 49 genes (Supplementary Tables S1-1–S1-5).
On the other hand, 5-azadC caused significant hypomethylation
of 520 genes but also induced hypermethylation of 83
genes (Supplementary Tables S1-1–S1-6). Similarly with HT29,
although the number of aberrantly methylated genes was higher,
the impact on cell viability is lesser compared to 5-FU (55%).
Combination of both 5-FU and 5-azadC resulted in even greater
number of differentially methylated genes; 762 genes were
hypermethylated and 589 were hypomethylated (Supplementary
Tables S1-1–S1-7) with profound reduction in cell viability
compared to 5-FU alone. Collectively, these results showed
that 5-azadC has successfully sensitized SW48 to 5-FU even
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FIGURE 4 | Top 10 of significantly differentially methylated genes. The blue circles represent average β-value of respective genes in non-recurrent samples
while black diamonds represent average β-value of respective genes in recurrent samples.
at lowest concentration tested (10 µM). Subsequent pathway
enrichment analysis revealed MAPK signaling pathway as one
of the significantly enriched pathway in this combinatorial drug
treatment (Table 3). Figure 8 illustrate the global methylation
changes in various treatment groups compared to untreated
control cells.
DISCUSSION
Many studies have shown that DNA methylation is an
important underlying mechanism for drug resistance which
subsequently posed the increased risk of recurrence. Despite
a growing consensus that methylation is a modulator of
cancer, the understanding of DNA methylation patterns of
recurrent CRC remains limited. To the best of our knowledge,
there is no publication addressing the genome-wide DNA
methylation analyses of recurrent CRC using the Illumina
Infinium HumanMethylation450 Beadchips. In our study, we
identified 4787 significantly differentially methylated genes
(P < 0.05) on methylation profiling of 43 non-recurrent
and five recurrent samples; 3112 genes were hyper- while
1675 genes were hypomethylated. Our results showed that
TABLE 2 | Five top pathways regulated by the hypermethylated genes in
recurrent CRCs compared to non-recurrent.
Pathway No. of genes P-value Enrichment
score
(A)
Pathway in cancer 68 0.013 1.304
MAPK signaling pathway 56 0.020 1.319
Focal adhesion 44 0.021 1.377
Calcium signaling pathway 39 0.025 1.394
Wnt signaling pathway 37 0.006 1.542
(B)
Pathway in cancer 40 0.036 1.362
Neuroactive ligand-receptor interaction 37 0.003 1.615
Endocytosis 31 7.58E-04 1.882
Regulation of actin cytoskeleton 31 0.008 1.611
Focal adhesion 29 0.011 1.612
recurrent CRC exhibit increased methylation levels compared
to non-recurrent group. Similar patterns have been observed
in chordomas where higher methylation level were observed in
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FIGURE 5 | Gene ontology (GO) enrichment analysis of (A) hypermethylated genes and (B) hypomethylated genes with. The genes were clustered according to
the cellular component, molecular function and biological process.
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FIGURE 6 | Predicted function of the five selected genes. These genes were mostly involved in cell cycle, cell growth, and cell differentiation.
recurrent chordomas compared to non-recurrent (Alholle et al.,
2015).
Most of the hypermethylated genes were commonly observed
in the CpG islands which are associated with promoter regions.
Our results are supported by a review from Jin et al. (2011)where
most studies showed hypermethylation occurring at CpG-rich
promoter regions. By contrast, hypomethylation often occurs in
the open sea area of the genome. McCabe et al. (2009) reported
that hypomethylation were observed in the intergenic region
as well as the gene body (Zheng, 2015) in which these two
regions are located in the open sea area (Ching et al., 2015).
Pathway enrichment analysis of hyper- and hypomethylated
genes revealed that most of the hypermethylated genes of
recurrent CRCs were involved in the MAPK signaling pathway
which specifically targets the apoptosis process. Cells which are
able to escape from the apoptosis process are associated with
chemotherapy resistance thus will increase the risk of recurrent
cancer (Kasibhatla and Tseng, 2003). In a few studies, TGFβ,
CASP3, DAXX, and p38 were found to be hypermethylated and
these genes are known to regulate the apoptosis process (Wagner
and Nebreda, 2009; Lee et al., 2012; McIlwain et al., 2013;
Pan et al., 2013). This is supported by Perry et al. (2006) where
most of the hypermethylation in cancer occurred in the genes
that regulate the apoptosis process and other cellular functions.
On the contrary, the hypomethylated genes of recurrent CRCs
are involved in the pathways in cancer particularly in regulating
the cell proliferation process and PI3K-AKT signaling pathway.
Among the genes involved in the proliferation process and
signaling pathway are PPFP, RXR, EGFR, PI3K, CCNA1, and
E2F (Balasubramanian et al., 2004; Yamazaki et al., 2005; Rolland,
2006; Yuan and Cantley, 2008; Webster et al., 2009; Reddi et al.,
2010). Hypomethylation could increase the expression of these
genes (Ehrlich, 2009) leading to the activation of PI3K-AKT
signaling pathway and proliferation process. The activation of
this pathway may increase the cell survival, hence resulting in the
increased risk of recurrence.
Three hypermethylated genes (CCNE1, CCNDBP1, and
PON3) and two hypomethylated genes (DDX43 and CHL1)
were selected for validation. These genes are involved in cell
cycle, cell proliferation and cell growth. CCNE1 belongs to the
highly conserved cyclin family and is an important component
in the cell cycle regulation. CCNE1 forms a complex with
CDK2 and is involved in the transition of G1 to S phase
as well as in the DNA replication (Hwang and Clurman,
2005). Increased expression of this gene can cause chromosomal
instability and lead to the formation of cancer such as breast
cancer, leukemia, non-small lung cancer, and others (Moroy and
Geisen, 2004). However, in this study we found that CCNE1
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FIGURE 7 | Growth studies and effects of combination treatments of 5-FU with 5-azadC. Treatment of (A) 5-Fluorouracil (5-FU), (B) 5-Aza-2′-deoxycytidine
(5-AzadC), (C) combination of 5-FU and 5-azadC on SW48 and HT29 for 72 h. Data is presented as mean ± SD, n = 9. ∗P < 0.05 compared to untreated cells.
is hypermethylated and its expression was downregulated in
recurrent CRCs compared to non-recurrent. This finding is
in concordance with the study by Kleivi et al. (2007) where
CCNE1 expression was lower in the carcinomatosis group
compared to primary cancer. The decreased expression of this
gene from primary CRC is associated with poor prognosis,
advanced stage and metastasis (Li et al., 2001). Apart from that,
a study from Nakayama et al. (2010) showed that increased
expression of CCNE1 in primary ovarian cancer was associated
with chemotherapy resistant and increased risk of recurrence.
Therefore, we believed that hypomethylation of this gene in non-
recurrent CRCs is associated with chemotherapy resistant which
subsequently contribute to recurrent CRCs. However, further
investigation is warranted to confirm this hypothesis.
TABLE 3 | Five top pathways regulated by the hypomethylated genes in
SW48 treated with combination drugs of 5-FU and 5-AzadC.
Pathway No. of genes P-value Enrichment score
Pathway in cancer 203 0.010 1.187
MAPK signaling pathway 173 0.080 1.219
Focal adhesion 129 0.050 1.207
Endocytosis 117 0.084 1.196
Axon guidance 91 0.013 1.327
Cyclin D type binding protein 1 (CCNDBP1), also known
as GC1P, is a tumor suppressor gene that is downregulated
in some cancers such as breast and prostate (Mostoslavsky
et al., 2006; Michishita et al., 2008). In colon cancer, the
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FIGURE 8 | Methylation profiling of SW48 and HT29 cell lines. Methylation profiling was carried out following incubation with 5-FU, 5-aza-dC and combination
of both drugs. Untreated cells were included as control. (A) Heatmap of the 50 top significantly differentially methylated genes in SW48. Red represent
hypermethylated genes while blue represent hypomethylated genes. (B) Heatmap of the top 50 significantly differentially methylated genes in HT29.
expression of this gene is lower in tumor tissues compared to
normal (Ma et al., 2007). Our study showed that CCNDBP1
is hypermethylated in recurrent CRCs compared to non-
recurrent, which could possibly explain the lower expression
of this gene. This is the first report of hypermethylation
of CCNDBP1 in recurrent CRCs. Paraoxonase 3 (PON3)
belongs to the paraoxonase families (PON1, PON2, PON3)
that helps in preventing oxidative stress and anti-inflammatory.
This gene is also involved in other diseases including cancer
(Devarajan et al., 2014). PON3 gene has high expression
in cancer tissues of the lung, liver and colon (Schweikert
et al., 2012). A study by Schweikert et al. (2012) showed
that the expression level of PON3 is different in various
stages of cancer. Stage I exhibit decreased expression of PON3
while stage II and III display increased expression of this
gene (Schweikert et al., 2012). In our study, we identified
hypermethylation of PON3. This is in line with the study by
Alholle et al. (2015), where PON3 was hypermethylated in
recurrent chordomas compared to the primary tumor. DDX43,
also known as helicase antigen (HAGE), is responsible for
cell proliferation and has a high expression level in cancer
compared to normal (Abdel-Fatah et al., 2014). Our microarray
profiling shows that DDX43 is hypomethylated in recurrent
CRCs. Hypomethylation of DDX43 induces the expression of
the gene and is strongly correlated with advanced disease
and poor prognosis in leukemia (Lin et al., 2014). DDX43
expression is increased in 50% of acute myeloid leukemia cases
(Adams et al., 2002) and high expression will activate the Ras
signaling pathway thus promoting cell proliferation (Ambrosini
et al., 2014). The dysregulation of this process may cause
the progression of cancer such as metastasis (Linley et al.,
2012).
Close Homolog of L1 (CHL1) is important for brain
development and neuron activities (Manderson et al., 2009).
It also plays a role in cancer progression (Qin et al., 2008)
and contributes to the metastasis process (Siesser and Maness,
2009). In recurrent CRCs, we identified hypomethylation of
this gene compared to non-recurrent CRCs. Hypomethylation
of CHL1 was also observed in metastatic oral squamous cell
carcinoma (OSCC) compared to non-metastatic tumor (Huang
et al., 2013). A previous reported the low expression of
CHL1 in majority of primary cancers and its expression is
increased in the metastatic or invasive tumor (Senchenko et al.,
2011).
The potential of demethylating agent such as 5-azadC in
sensitizing resistant cancer cells to chemotherapeutic agent
in CRC in vitro model has already been studied by several
groups (Fang et al., 2004; Mossman et al., 2010; Khamas et al.,
2012; Flis et al., 2014). Nevertheless, the global methylation
changes following the treatment is not well-characterized and
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the aforementioned studies pre-selected certain genes for further
investigation. The action of 5-azadC is not gene-specific and vary
across different cell lines thus it is important to know which
genes or pathway will be affected by this agent. Furthermore,
the chemotherapeutic agent used by previous studies was
Trichostatin A (TSA) (Fang et al., 2004; Mossman et al., 2010)
which is not commonly practiced by our oncologist. To be
more relevant with our population, we investigated the effect
of 5-FU chemosensitization by 5-azadC in hypermethylated and
hypomethylated cell lines and profiled the global methylation
changes caused by the agents whether singular or in combination.
We observed that the reduction in cancer cell viability is
significantly greater in SW48 compared to HT29 when treated
with both 5-FU and 5-azadC. This is in concordance with other
study which showed that there was an increase in inhibition of
CRC cells growth after combinatorial treatment with both agents
(Flis et al., 2014).
SW48 cells treated with combined drugs showed decrease
in methylation level, particularly in genes that involved in
MAPK signaling pathway which specifically target p53 signaling
pathway. P53 is a tumor suppressor gene that helps in regulates
apoptosis process and cell cycles (Nieto et al., 2004). DNA
damage induced by chemotherapy have been shown to activate
p53 signaling pathway which can trigger the apoptosis process.
Our study revealed demethylation of genes involve in p53
signaling pathway in SW48 which then could possibly induce
the activation of these genes. As these genes become activated,
the presence of 5-FU will cause DNA damage and therefore p53
signaling pathway could be re-activated and lead to apoptosis
process. Hypomethylation of genes involved in Fas mediated
apoptosis pathway which were FAS, DAXX, ASK1, and MAX
was also observed in SW48 treated with combined drugs.
DAXX gene will bind to FAS death domain, and overexpression
of DAXX will initiates Fas-induced apoptosis through the
activation of ASK1, MKK6, p38, and MAX genes (Yang et al.,
1997).
This study has several obvious limitations. First, the number
of recurrent CRC cases used in this study is small thus we
compensated with increasing the sample size of the non-
recurrent CRCs and performed genome-wide profiling instead of
targeting specific genes. Secondly, we did not manage to obtain
a matched primary and recurrent cancer tissues from the same
patient. It would be ideal to perform the comparison using the
cancer tissues from the same individual.
CONCLUSION
To the best of our knowledge, our study is the first to
address the genome wide methylation changes in recurrent
CRCs and non-recurrent CRCs. The increased in global
methylation levels were observed in the recurrent cases.
Our study revealed several potentially biologically important
genes – CCNE1, CCNDBP1, PON3, CHL1, and DDX43
that may represent new potential therapeutic targets for
patients with chemoresistant phenotype. Our in vitro findings
suggest that 5-azadC-mediated restoration of 5-FU sensitivity
is mediated at least in part by MAPK signaling pathway.
Further investigation is needed in order to completely
understand the involvement of these genes in the cancer
recurrence.
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